Zhitong Finance App News, Cinda Biotech (01801.HK) announced that in the first quarter of 2026, the company recorded product revenue of more than RMB 3.8 billion, an increase of more than 50% over the previous year. This strong momentum confirms the successful implementation of the company's “two-wheel drive” strategy. The company's leading position in the field of oncology is becoming more and more prominent. Five new tyrosine kinase inhibitors (TKIs) were added to the National Medical Insurance Drug List (NRDL) and achieved rapid release. At the same time, the comprehensive product line has become a strong emerging driving force for the company's revenue growth, mainly due to the excellent performance of core products such as Xinermei® (Maxidopeptide injection), Cinpirac® (tolecimab injection), and Cinpimin® (teturozumab N01 injection).

Zhitong Finance App News, Cinda Biotech (01801.HK) announced that in the first quarter of 2026, the company recorded product revenue of more than RMB 3.8 billion, an increase of more than 50% over the previous year. This strong momentum confirms the successful implementation of the company's “two-wheel drive” strategy. The company's leading position in the field of oncology is becoming more and more prominent. Five new tyrosine kinase inhibitors (TKIs) were added to the National Medical Insurance Drug List (NRDL) and achieved rapid release. At the same time, the comprehensive product line has become a strong emerging driving force for the company's revenue growth, mainly due to the excellent performance of core products such as Xinermei® (Maxidopeptide injection), Cinpirac® (tolecimab injection), and Cinpimin® (teturozumab N01 injection).